A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Phase 3
975
about 7.6 years
50–85
152 sites in AR, AZ, CA +30
What this study is about
This trial is testing a treatment called pozelimab, either alone or with cemdisiran, for people with geographic atrophy (GA) caused by age-related macular degeneration (AMD). The goal is to see how quickly GA progresses in eyes treated with cemdisiran alone or in combination with pozelimab compared to those treated with a placebo.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Cemdisiran
- 2.Take Placebo
- 3.Take Pozelimab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
pozelimab
Secondary: Change from baseline in Low-Contrast quantitative Visual Acuity (LC-qVA), Change from baseline in Low-Luminance Low-Contrast quantitative Visual Acuity (LL-LC-qVA), Change from baseline in concentration of total Complement component 5 (C5), Change from baseline in quantitative Contrast Sensitivity Function (qCSF), Occurrence of Treatment-Emergent Adverse Events (TEAEs), Severity of TEAEs